Do you consider eniluracil a long shot because of history of failed trials. Part of the attraction for me of ADH is the simplicity of there argument for why there approach should work. It is suprising to me that GSK did not think of this.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.